 |
- BioStar Capital and Cue Growth co-lead financing to accelerate pivotal trial readiness and expand the ventricular tachycardia (VT) treatment market
- New board leadership reflects Field's momentum and readiness for pivotal execution
CARDIFF-BY-THE-SEA, Calif., July 1, 2025 /PRNewswire/ -- Field Medical, Inc., a clinical-stage company redefining cardiac ablation with next-generation pulsed field ablation (PFA) technology, today announced the close of a $35 million Series B financing round co-led by BioStar Capital and Cue Growth, with participation from existing strategic investors.
The Series B financing will support the initiation of the company's pivotal VERITAS trial, advance the FieldForce Ablation System development, and further expand Field Medical's clinical and regulatory capabilities. The raise was catalyzed in part by strong pilot data presented at the 2025 Heart Rhythm Society meeting. With this round, Field Medical has raised $75 million to date, further solidifying its leadership in PFA innovation for complex arrhythmias.
"Ventricular tachycardia is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need," said Steven Mickelsen, MD, founder and CEO of Field Medical. "What is exciting is how VT is mirroring the early days of the AF market, strong clinical demand unmet by existing technology. We are poised to unlock this opportunity with our next-generation therapy built for speed, precision and real clinical progress, advancing toward pivotal readiness and redefining what is possible in VT care for high-risk patients."
"Field Medical's transformative technology is doing what few companies dare to do – tackling one of the most difficult and under-addressed challenges in cardiology with real innovation and urgency," said Louis Cannon, MD, founder and senior managing director of BioStar Capital. "Their physician-led team brings the right insight, and their FieldForce platform brings the right tools. We're proud to support this next chapter as they move closer to transforming VT care."
"This round reflects the momentum building behind Field Medical, not only from our clinical results, but also from the strength of our business fundamentals," said Oskar Dadason, CFO of Field Medical. "Our strong showing at HRS attracted institutional investor interest and reinforced continued support from existing investors, speaking volumes about the confidence in our technology, strategy, and leadership."
Board of Directors Update
In alignment with its accelerated growth trajectory, Field Medical announced updates to its Board of Directors:
- Steven Mickelsen, MD, Founder and CEO, Field Medical – Electrophysiologist, serial entrepreneur, and inventor of pulsed field ablation technologies including FARAPULSE™ and FieldForce™.
- Mark Wisniewski, CFO of Enterra Medical – Medtech operator with deep buy-side experience and M&A leadership, guiding Field through its next phase of value creation as chairperson of the Field Medical board.
- Marlou Janssen, Board Member at Field Medical, Sonion, Acarix, EBAMed, and Inspiration Healthcare – Experienced executive and board member, former President of Biotronik U.S. and VP/GM at EPD Solutions Philips, bringing decades of commercial, product and clinical strategy leadership in cardiology and emerging medtech.
- Alexei Mlodinow, MD, MBA – Surgeon by training, serial entrepreneur, and investor with a track record in medtech innovation and multiple exits, including the $140M acquisition of Surgical Innovation Associates.
- Ben Cannon, Founding Partner, Cue Growth – Seasoned venture capital investor with deep experience scaling growth-stage companies, offering institutional governance expertise and a performance-driven lens to support Field as the company scales.
About Field Medical® Inc.
Founded in 2022, Field Medical is advancing pulsed field ablation (PFA) technologies for the treatment of complex cardiac arrhythmias. Led by PFA pioneer Dr. Steven Mickelsen, the company's FieldForceâ„¢ Ablation System combines breakthrough catheter design with proprietary FieldBendingâ„¢ energy to enable rapid, targeted ablation. In 2024, the company received Breakthrough Device Designation and was selected for the FDA TAP Pilot Program for its VT indication. To learn more about the company's clinical focus and technology, watch the Heart Rhythm 2025 Satellite Symposium replay, PFA in the Ventricle: The Future of Ablation.
For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn and X.
The FieldForceâ„¢ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use.
Media Contact
Holly Windler
holly.windler@gmail.com
Photo - https://mma.prnasia.com/media2/2722619/Field_Medical_FieldForce__Ablation_System_Next_generation_PFA.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2574173/Field_Medical_Logo_Block_WhiteOnBlack_Logo.jpg?p=medium600
- BioStar Capital and Cue Growth co-lead financing to accelerate pivotal trial readiness and expand the ventricular tachycardia (VT) treatment market
- New board leadership reflects Field's momentum and readiness for pivotal execution
CARDIFF-BY-THE-SEA, Calif., July 1, 2025 /PRNewswire/ -- Field Medical, Inc., a clinical-stage company redefining cardiac ablation with next-generation pulsed field ablation (PFA) technology, today announced the close of a $35 million Series B financing round co-led by BioStar Capital and Cue Growth, with participation from existing strategic investors.
The Series B financing will support the initiation of the company's pivotal VERITAS trial, advance the FieldForce Ablation System development, and further expand Field Medical's clinical and regulatory capabilities. The raise was catalyzed in part by strong pilot data presented at the 2025 Heart Rhythm Society meeting. With this round, Field Medical has raised $75 million to date, further solidifying its leadership in PFA innovation for complex arrhythmias.
"Ventricular tachycardia is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need," said Steven Mickelsen, MD, founder and CEO of Field Medical. "What is exciting is how VT is mirroring the early days of the AF market, strong clinical demand unmet by existing technology. We are poised to unlock this opportunity with our next-generation therapy built for speed, precision and real clinical progress, advancing toward pivotal readiness and redefining what is possible in VT care for high-risk patients."
"Field Medical's transformative technology is doing what few companies dare to do – tackling one of the most difficult and under-addressed challenges in cardiology with real innovation and urgency," said Louis Cannon, MD, founder and senior managing director of BioStar Capital. "Their physician-led team brings the right insight, and their FieldForce platform brings the right tools. We're proud to support this next chapter as they move closer to transforming VT care."
"This round reflects the momentum building behind Field Medical, not only from our clinical results, but also from the strength of our business fundamentals," said Oskar Dadason, CFO of Field Medical. "Our strong showing at HRS attracted institutional investor interest and reinforced continued support from existing investors, speaking volumes about the confidence in our technology, strategy, and leadership."
Board of Directors Update
In alignment with its accelerated growth trajectory, Field Medical announced updates to its Board of Directors:
- Steven Mickelsen, MD, Founder and CEO, Field Medical – Electrophysiologist, serial entrepreneur, and inventor of pulsed field ablation technologies including FARAPULSE™ and FieldForce™.
- Mark Wisniewski, CFO of Enterra Medical – Medtech operator with deep buy-side experience and M&A leadership, guiding Field through its next phase of value creation as chairperson of the Field Medical board.
- Marlou Janssen, Board Member at Field Medical, Sonion, Acarix, EBAMed, and Inspiration Healthcare – Experienced executive and board member, former President of Biotronik U.S. and VP/GM at EPD Solutions Philips, bringing decades of commercial, product and clinical strategy leadership in cardiology and emerging medtech.
- Alexei Mlodinow, MD, MBA – Surgeon by training, serial entrepreneur, and investor with a track record in medtech innovation and multiple exits, including the $140M acquisition of Surgical Innovation Associates.
- Ben Cannon, Founding Partner, Cue Growth – Seasoned venture capital investor with deep experience scaling growth-stage companies, offering institutional governance expertise and a performance-driven lens to support Field as the company scales.
About Field Medical® Inc.
Founded in 2022, Field Medical is advancing pulsed field ablation (PFA) technologies for the treatment of complex cardiac arrhythmias. Led by PFA pioneer Dr. Steven Mickelsen, the company's FieldForceâ„¢ Ablation System combines breakthrough catheter design with proprietary FieldBendingâ„¢ energy to enable rapid, targeted ablation. In 2024, the company received Breakthrough Device Designation and was selected for the FDA TAP Pilot Program for its VT indication. To learn more about the company's clinical focus and technology, watch the Heart Rhythm 2025 Satellite Symposium replay, PFA in the Ventricle: The Future of Ablation.
For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn and X.
The FieldForceâ„¢ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use.
Media Contact
Holly Windler
holly.windler@gmail.com
Photo - https://mma.prnasia.com/media2/2722619/Field_Medical_FieldForce__Ablation_System_Next_generation_PFA.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2574173/Field_Medical_Logo_Block_WhiteOnBlack_Logo.jpg?p=medium600
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform
|
VICTORIA, Seychelles, May 18, 2026 /PRNewswire/ -- MEXC, a pioneer in 0-fee digital asset trading, has completed a comprehensive AI product upgrade with the official launch of the industry's first fully free and open trading agent: AI Strategy. This marks the evolution of MEXC AI from a decision-support tool into an autonomous trading agent capable of understanding user intent and independently executing trades, creating a complete end-to-end trading workflow.
In traditional trading, every step, from identifying opportunities to executing trades, requires manual involvement, making the process both time-consuming and highly susceptible to emotional decision-making. MEXC AI Strategy redefines this workflow. Users simply express their ideas, while the AI handles intent analysis, strategy generation, continuous market monitoring, and automated execution. MEXC AI Strategy offers three key highlights:
Generate Complex Strategies with Natural Language
Users no longer need quantitative trading expertise or coding skills. By simply chatting with MEXC AI, they can create personalized trading strategies tailored to their own preferences. The system supports not only common technical indicators, but also complex conditional strategies across multiple platforms and data sources. For example, users can set instructions such as: "Go long when ETH breaks out of a bilateral pattern, with an 8% take-profit target," or "Go long when Elon Musk posts on X and the token price rises." The AI can automatically understand the intent and generate the corresponding strategy.
Real-Time Social Media Monitoring to Capture Opportunities Faster
In news-driven markets, information asymmetry often determines profit and loss. MEXC AI Strategy can monitor real-time signals from social platforms such as X, continuously tracking influential figures and market sentiment. Strategies can be triggered within seconds after relevant events occur, helping users seize market opportunities at the earliest possible moment.
24/7 Automated Market Monitoring, Free for Everyone
Powered by integration with leading AI models, MEXC AI Strategy continuously monitors and executes trades around the clock, allowing users to stay active in the market without constantly watching charts. The feature is also fully open and free to use, enabling anyone to access AI-powered automated trading with zero barriers to entry.
For detailed guides and FAQs, please visit MEXC Learn.
With this latest upgrade, the MEXC AI product ecosystem has become even more comprehensive. The platform's Smart Chart displays AI-powered price predictions, probability-of-rise indicators, and upcoming event alerts directly beneath candlestick charts, transforming market analysis that users previously had to piece together themselves into structured, actionable insights. The AI Consultant provides personalized recommendations based on users' actual portfolio positions, while AI Strategy converts users' market views directly into executable strategies and automated orders. Together, the three features cover the complete trading workflow: from discovery to analysis and finally to execution.
Vugar Usi, CEO of MEXC, said:
"Zero-fee trading removed the cost barrier to trading, while MEXC AI is removing an even more critical barrier: execution. While much of the industry focuses AI capabilities on professional infrastructure, MEXC has chosen to start from the real workflows of everyday traders, truly understanding user intent and helping them execute more efficiently. The goal of MEXC AI is to ensure that every opportunity users recognize can actually be captured, delivering on our promise of "Infinite Opportunities."
In the first quarter of 2026, MEXC AI-related features recorded approximately 140,000 daily active users, while cumulative quarterly active users surpassed 1.04 million, reflecting growing market demand for AI-powered trading assistance tools. Users can now log in through the official MEXC website or app to experience the latest MEXC AI landing page.
About MEXC
MEXC is the world's fastest-growing cryptocurrency exchange, trusted by more than 40 million users across 170+ markets. Built on a user-first philosophy, MEXC offers industry-leading 0-fee trading and access to over 3,000 digital assets. As the Gateway to Infinite Opportunities, MEXC provides a single platform where users can easily trade cryptocurrencies alongside tokenized assets, including stocks, ETFs, commodities, and precious metals.
MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC
VICTORIA, Seychelles, May 18, 2026 /PRNewswire/ -- MEXC, a pioneer in 0-fee digital asset trading, has completed a comprehensive AI product upgrade with the official launch of the industry's first fully free and open trading agent: AI Strategy. This marks the evolution of MEXC AI from a decision-support tool into an autonomous trading agent capable of understanding user intent and independently executing trades, creating a complete end-to-end trading workflow.
In traditional trading, every step, from identifying opportunities to executing trades, requires manual involvement, making the process both time-consuming and highly susceptible to emotional decision-making. MEXC AI Strategy redefines this workflow. Users simply express their ideas, while the AI handles intent analysis, strategy generation, continuous market monitoring, and automated execution. MEXC AI Strategy offers three key highlights:
Generate Complex Strategies with Natural Language
Users no longer need quantitative trading expertise or coding skills. By simply chatting with MEXC AI, they can create personalized trading strategies tailored to their own preferences. The system supports not only common technical indicators, but also complex conditional strategies across multiple platforms and data sources. For example, users can set instructions such as: "Go long when ETH breaks out of a bilateral pattern, with an 8% take-profit target," or "Go long when Elon Musk posts on X and the token price rises." The AI can automatically understand the intent and generate the corresponding strategy.
Real-Time Social Media Monitoring to Capture Opportunities Faster
In news-driven markets, information asymmetry often determines profit and loss. MEXC AI Strategy can monitor real-time signals from social platforms such as X, continuously tracking influential figures and market sentiment. Strategies can be triggered within seconds after relevant events occur, helping users seize market opportunities at the earliest possible moment.
24/7 Automated Market Monitoring, Free for Everyone
Powered by integration with leading AI models, MEXC AI Strategy continuously monitors and executes trades around the clock, allowing users to stay active in the market without constantly watching charts. The feature is also fully open and free to use, enabling anyone to access AI-powered automated trading with zero barriers to entry.
For detailed guides and FAQs, please visit MEXC Learn.
With this latest upgrade, the MEXC AI product ecosystem has become even more comprehensive. The platform's Smart Chart displays AI-powered price predictions, probability-of-rise indicators, and upcoming event alerts directly beneath candlestick charts, transforming market analysis that users previously had to piece together themselves into structured, actionable insights. The AI Consultant provides personalized recommendations based on users' actual portfolio positions, while AI Strategy converts users' market views directly into executable strategies and automated orders. Together, the three features cover the complete trading workflow: from discovery to analysis and finally to execution.
Vugar Usi, CEO of MEXC, said:
"Zero-fee trading removed the cost barrier to trading, while MEXC AI is removing an even more critical barrier: execution. While much of the industry focuses AI capabilities on professional infrastructure, MEXC has chosen to start from the real workflows of everyday traders, truly understanding user intent and helping them execute more efficiently. The goal of MEXC AI is to ensure that every opportunity users recognize can actually be captured, delivering on our promise of "Infinite Opportunities."
In the first quarter of 2026, MEXC AI-related features recorded approximately 140,000 daily active users, while cumulative quarterly active users surpassed 1.04 million, reflecting growing market demand for AI-powered trading assistance tools. Users can now log in through the official MEXC website or app to experience the latest MEXC AI landing page.
About MEXC
MEXC is the world's fastest-growing cryptocurrency exchange, trusted by more than 40 million users across 170+ markets. Built on a user-first philosophy, MEXC offers industry-leading 0-fee trading and access to over 3,000 digital assets. As the Gateway to Infinite Opportunities, MEXC provides a single platform where users can easily trade cryptocurrencies alongside tokenized assets, including stocks, ETFs, commodities, and precious metals.
MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
MEXC Launches AI Strategy, Advancing Its End-to-End AI Trading Ecosystem
MEXC Launches AI Strategy, Advancing Its End-to-End AI Trading Ecosystem
